In a 65-year-old female with hemoglobin A1c of 12% and random blood glucose of 290 mg/dL, what is the next step in drug management?

Start Basal Insulin Immediately

For this 65-year-old woman with HbA1c 12% and random blood glucose 290 mg/dL, initiate basal insulin at 10 units daily or 0.1-0.2 units/kg/day, titrating by 2 units every 3 days to reach fasting glucose goal without hypoglycemia. 1

Rationale for Insulin as First-Line Injectable

The 2025 ADA Standards explicitly recommend insulin as the first injectable therapy when:

• A1C ≥10% (this patient has 12%)
• Blood glucose ≥300 mg/dL (this patient has 290 mg/dL, approaching threshold)
• Symptoms of hyperglycemia are present 1

While this patient's glucose is slightly below 300 mg/dL, the HbA1c of 12% is substantially above the 10% threshold, making insulin the appropriate initial injectable therapy.

Specific Insulin Initiation Protocol

Starting Dose

• 10 units once daily OR
• 0.1-0.2 units/kg per day 1

Choose either NPH at bedtime or a long-acting basal analog (glargine, detemir, or degludec). Basal analogs may be preferred in older adults to reduce hypoglycemia risk 2.

Titration Strategy

• Set fasting plasma glucose goal (typically 90-150 mg/dL for a 65-year-old) 1, 2
• Increase by 2 units every 3 days until fasting goal achieved without hypoglycemia 1
• If hypoglycemia occurs: identify cause; if unclear, reduce dose by 10-20% 1

Concurrent Oral Agent Considerations

Do not delay metformin if not already prescribed and no contraindications exist (eGFR ≥30 mL/min/1.73 m²) 2. Metformin remains first-line oral therapy even when starting insulin.

Adding GLP-1 RA or Dual GIP/GLP-1 RA

Once basal insulin is titrated and if A1C remains above goal:

• Consider adding GLP-1 RA or dual GIP/GLP-1 RA to the insulin regimen 1
• These agents provide additional A1C lowering (1-2% reduction) with weight loss benefit rather than weight gain 1, 3
• May use fixed-ratio combination products (IDegLira or iGlarLixi) if appropriate 1

Research suggests GLP-1 RAs can achieve similar or superior glycemic control compared to insulin at very high baseline A1C levels (≥10%), with mean reductions of 2.5-3.1% 3. However, current guidelines prioritize insulin first at these extreme elevations, particularly given the rapid glucose-lowering needed.

Age-Specific Considerations for This 65-Year-Old

At age 65, this patient warrants attention to:

• Hypoglycemia risk: Use conservative fasting glucose targets (90-150 mg/dL rather than tighter goals) 2
• Simplicity: Morning dosing of basal insulin may improve adherence over bedtime NPH 2
• Glucagon prescription: Consider prescribing emergency glucagon given insulin initiation 1

Monitoring and Reassessment

• Reassess every 3-6 months to avoid therapeutic inertia 1
• Monitor for signs of overbasalization: elevated bedtime-to-morning glucose differential, hypoglycemia, high glucose variability 1
• If A1C remains >goal after optimizing basal insulin, add prandial insulin starting with largest meal (4 units or 10% of basal dose) 1

Common Pitfalls to Avoid

Do not use GLP-1 RA alone as first injectable at this HbA1c level—guidelines reserve this for lower baseline A1C or when insulin is not preferred 1. The HbA1c of 12% demands the more potent and rapid glucose-lowering of insulin.

Do not delay treatment intensification—therapeutic inertia at this severe hyperglycemia level increases risk of complications 1.

Do not use sliding scale insulin alone—basal insulin with systematic titration is superior to reactive sliding scale approaches 2.